PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN

PURPOSE: PD-L1 status by immunohistochemistry (IHC) is prognostic in metastatic renal cell carcinoma (mRCC) and its role as a potential predictive biomarker is under investigation. Using tumor tissue from the METEOR () and CABOSUN () clinical trials, we explored whether PD-L1 expression and the exte...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Flaifel, Abdallah, Xie, Wanling, Braun, David A., Ficial, Miriam, Bakouny, Ziad, Nassar, Amin H., Jennings, Rebecca B., Escudier, Bernard, George, Daniel J., Motzer, Robert J., Morris, Michael J., Powles, Thomas, Wang, Evelyn, Huang, Ying, Freeman, Gordon J., Choueiri, Toni K., Signoretti, Sabina
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801080/
https://ncbi.nlm.nih.gov/pubmed/31371341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1135
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires